Please assess the completion status of the following clinical trial:

Trial Title: Microbicide Safety and Acceptability in Young Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Participants in Stage 1A (non sex-workers):~1. Willing and able to provide written informed consent to take part in the study~2. Willing and able to communicate in English or Spanish~3. Must agree not to participate in other drug trials~4. Biologically male and identifies as male~5. Age 18-30 years at screening~6. HIV-1 status antibody negative or unknown per patient report~7. Understands and agrees to local STI reporting requirements~8. Able and willing to provide adequate information for locator purposes~9. Availability to return for all study visits, barring unforeseen circumstances~10. A history of consensual RAI at least once in past month~11. Reporting at least one occasion of unprotected RAI in the prior year\* In order to identify participants at increased risk for acquiring HIV~Inclusion Criteria for Participants in Stage 1A (sex-workers):~1. Willing and able to provide written informed consent to take part in the study~2. Willing and able to communicate in English or Spanish~3. Must agree not to participate in other drug trials~4. Biologically male, including male-to-female transgender women~5. Age 18-30 years at screening~6. HIV-1 status antibody negative or unknown per patient report~7. Understands and agrees to local STI reporting requirements~8. Able and willing to provide adequate information for locator purposes~9. Availability to return for all study visits, barring unforeseen circumstances~10. A history of consensual RAI at least once in past month~11. Reporting at least one occasion of unprotected RAI in the prior year\*~12. Reporting at least two occasions of RAI as part of transactional sex (i.e., having received money or other goods/services in exchange for sex) in the prior 2 months\*~    * In order to identify participants at increased risk for acquiring HIV~Inclusion Criteria for Participants in Stage 1B (both sex workers and non sex-workers):~1. Completed Stage 1A~2. HIV-1 uninfected at screening based on HIV rapid test results~3. Reports unprotected RAI in the prior three months on at least one occasion\* In order to obtain acceptability data from individuals most likely to benefit from microbicide availability~4. Availability to return for all Stage 1B visits, barring unforeseen circumstances~Inclusion Criteria for Participants in Stage 2:~1. Completed study stage 1AB~2. HIV-1 uninfected at screening based on HIV rapid test results~3. Availability to return for all Stage 2 visits, barring unforeseen circumstances~Exclusion Criteria for Participants in Stage 1A (both sex workers and non sex-workers):~1. Any condition or prior therapy that, in the opinion of the investigator, would make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease~Exclusion Criteria for Participants in Stage 1B (both sex workers and non sex-workers):~1. Clinical or laboratory diagnosis of active rectal infection requiring treatment per current CDC guidelines. Infections requiring treatment include Chlamydia (CT), gonorrhea (GC), syphilis, active HSV lesions, chancroid, genital sores or ulcers, and if clinically indicated, genital warts. Note that an HSV-2 seropositive diagnosis with no active lesions is allowed, since treatment is not required~2. Positive Hepatitis B surface antigen test indicating hepatitis B infection~3. Allergy to methylparaben, propylparaben, or latex~4. History of significant drug allergy or recurrent urticaria~5. History of inflammatory bowel disease~6. Currently engage or plan to engage in unprotected RAI with HIV-infected partners~7. By participant report planning to receive another investigational drug while participating in this study~8. Any other condition or prior therapy that, in the opinion of the investigator, would make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease~Exclusion Criteria for Participants in Stage 2:~1. Meet any of the exclusion criteria for Stage 1B~2. Reporting a history of transactional sex (i.e., having received money or other goods/services in exchange for sex) in the prior 6 months~3. Undergoing or completed gender reassignment~4. Grade 2 or higher liver function, creatinine, coagulation, electrolyte, or hematology abnormality in accordance with DAIDS toxicity table values (normal values based on site specific laboratory criteria) at screening (or Visit 2 PT/INR for coagulation), and confirmed by retest/and or redraw~5. History of significant gastrointestinal bleeding~6. History of inflammatory bowel disease~7. Abnormalities of the rectal mucosa, or significant rectal symptom(s), which in the opinion of the clinician represents a contraindication to biopsy (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids~8. Per participant report, anticipated use and/or unwillingness to abstain from the following medications during the period of Stage 2 study participation:~   1. Heparin, including Lovenox®~  2. Warfarin~  3. Plavix® (clopidogrel bisulfate)~  4. Aspirin \>81 mg per day~  5. Non-steroidal anti-inflammatory drugs (NSAIDS)~  6. Any other drugs that are associated with increased likelihood of bleeding following rectal biopsy~9. By participant report, use of systemic immunomodulatory medications within the 4 weeks prior to the Stage 2 Enrollment Visit and throughout study participation~10. By participant report, use of rectally administered medications, rectally administered products (including condoms) containing N-9, or any investigational products within the 2 weeks or 10 half-lives of the drug, whichever is longer, prior to the Stage 2 Enrollment Visit, or is planning to receive another investigational drug while participating in this study~11. Any other condition or prior therapy that, in the opinion of the investigator, would make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease -

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- HEC Placebo Gel (Type: PLACEBO_COMPARATOR): In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
- Tenofovir 1% Gel (Type: ACTIVE_COMPARATOR): In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.

Based on this trial design, predict the completion outcome and termination type (if applicable).